These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 15944334)

  • 1. Rapamycin: a new string to the antiproteinuric bow?
    Brunskill NJ
    J Am Soc Nephrol; 2005 Jul; 16(7):1878-9. PubMed ID: 15944334
    [No Abstract]   [Full Text] [Related]  

  • 2. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
    Stephany BR; Boumitri M; Budev M; Alao B; Poggio ED
    J Heart Lung Transplant; 2009 Jun; 28(6):564-71. PubMed ID: 19481016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mammalian target of rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass.
    Diekmann F; Rovira J; Carreras J; Arellano EM; Bañón-Maneus E; Ramírez-Bajo MJ; Gutiérrez-Dalmau A; Brunet M; Campistol JM
    J Am Soc Nephrol; 2007 Oct; 18(10):2653-60. PubMed ID: 17804674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks.
    Diekmann F; Campistol JM
    Nephrol Dial Transplant; 2006 Mar; 21(3):562-8. PubMed ID: 16361278
    [No Abstract]   [Full Text] [Related]  

  • 5. Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria.
    Saurina A; Campistol JM; Piera C; Diekmann F; Campos B; Campos N; de las Cuevas X; Oppenheimer F
    Nephrol Dial Transplant; 2006 Feb; 21(2):488-93. PubMed ID: 16280369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Considerations in sirolimus use in the early and late post-transplant periods.
    Patel SJ; Elliott EN; Knight RJ; Gaber LW; Gaber AO
    Expert Opin Drug Saf; 2009 Jul; 8(4):421-34. PubMed ID: 19522662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapamycin and chronic kidney disease: beyond the inhibition of inflammation.
    Liu Y
    Kidney Int; 2006 Jun; 69(11):1925-7. PubMed ID: 16724087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.
    Falger JC; Mueller T; Arbeiter K; Boehm M; Regele H; Balzar E; Aufricht C
    Pediatr Transplant; 2006 Aug; 10(5):565-9. PubMed ID: 16856992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.
    Falger JC; Mueller T; Arbeiter K; Boehm M; Regele H; Balzar E; Aufricht C
    Pediatr Transplant; 2006 Jun; 10(4):474-8. PubMed ID: 16712606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus--challenging current perspectives.
    Buhaescu I; Izzedine H; Covic A
    Ther Drug Monit; 2006 Oct; 28(5):577-84. PubMed ID: 17038868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of murine lupus disease in (NZBxNZW)F1 mice by sirolimus treatment.
    Ramos-Barrón A; Piñera-Haces C; Gómez-Alamillo C; Santiuste-Torcida I; Ruiz JC; Buelta-Carrillo L; Merino R; de Francisco AL; Arias M
    Lupus; 2007; 16(10):775-81. PubMed ID: 17895299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sirolimus in de novo heart transplant recipients with severe renal impairment.
    Vazquez de Prada JA; Vilchez FG; Cobo M; Ruisanchez C; Valls MF; Ruano J; Piñera C; Duran RM
    Transpl Int; 2006 Mar; 19(3):245-8. PubMed ID: 16441775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirolimus in renal transplantation.
    Morath C; Arns W; Schwenger V; Mehrabi A; Fonouni H; Schmidt J; Zeier M
    Nephrol Dial Transplant; 2007 Sep; 22 Suppl 8():viii61-viii65. PubMed ID: 17890266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of rapamycin on active Heymann nephritis.
    Naumovic R; Jovovic D; Basta-Jovanovic G; Miloradovic Z; Mihailovic-Stanojevic N; Aleksic T; Jovanovic D
    Am J Nephrol; 2007; 27(4):379-89. PubMed ID: 17570905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic significance of proteinuria selectivity].
    Sasinka M; Pavlovic M; Páleníková O; Getlík A; Slugen I; Kaiserová E
    Vnitr Lek; 1980 Feb; 26(2):187-93. PubMed ID: 7361472
    [No Abstract]   [Full Text] [Related]  

  • 16. Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction.
    Ruiz JC; Campistol JM; Sánchez-Fructuoso A; Rivera C; Oliver J; Ramos D; Campos B; Arias M; Diekmann F
    Nephrol Dial Transplant; 2006 Nov; 21(11):3252-7. PubMed ID: 16954170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-rapamycin proteinuria: incidence, evolution, and therapeutic handling at a single center.
    Pinheiro HS; Amaro TA; Braga AM; Bastos MG
    Transplant Proc; 2006 Dec; 38(10):3476-8. PubMed ID: 17175309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The treatment of multifocal choroiditis associated choroidal neovascularization with sirolimus (rapamycin).
    Nussenblatt RB; Coleman H; Jirawuthiworavong G; Davuluri G; Potapova N; Dahr SS; Ragheb JA; Levy-Clarke G
    Acta Ophthalmol Scand; 2007 Mar; 85(2):230-1. PubMed ID: 17305748
    [No Abstract]   [Full Text] [Related]  

  • 19. Review of symposium. Sirolimus in kidney transplantation.
    Schena FP
    Transplantation; 2009 Apr; 87(8 Suppl):S30-3. PubMed ID: 19384185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel immunosuppressive agent, sirolimus, in the treatment of Kaposi's sarcoma in a renal transplant recipient.
    Yilmaz R; Akoglu H; Kirkpantur A; Kilickap S; Arici M; Altun B; Aki T; Erdem Y; Yasavul U; Turgan C
    Ren Fail; 2007; 29(1):103-5. PubMed ID: 17365918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.